Costo directo demestral por artritis reumatoidea en pacientes que concurren a un hospital universitario
DOI:
https://doi.org/10.31053/1853.0605.v60.n2.36661Keywords:
Direct cost, rheumatoid arthritisAbstract
Introduction: There are no medical puhlical.ions with economic analysis of rheumatoid arthritis patients (RA) from Argentina are lackirig. The objective of the present study is to determine the direct cost and its breakdown in patients with RA. Material and Methods: Fifty.- two patients who met the American College of Rheumatology RA entena were included. Direct cost was calculated over a follow-up period of 6 months during year 2001. Variables were analyzed with Student's T test, Mann-Whitney U Test, cor ANOVA as corresponded. P values <0.05 were considered significant. Results: The mean monthly home income was $426.6 SD 272. The mean half-yearly direct costs was $677,5 SD 376.2. The components of the direct cost were identified and the mean for medication cost vas $606.7 (89%), for lab tests was $45,5 (7%), for medical attention $12,5 (2%) and other costs
$2.4. No differences in total cost or in medication cost were found when compared considering age, evolution time of RA or HAQ scores. Conclusion: Haif- yearly direct cost in RA is excessively high considering the monthly mean income of the patients being analyzed. The cost of medication was the principal component of the direct cost.
Downloads
References
Alonso HO: El clínico, el generalista y la economía. Medicina 50: 566-7. 1990. American College of Rheumatology ad hoc Committee on Clinical Guideliries: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 39: 713-22. 1996.
Ariza-Ariza R, Mestanza-Peralta M, Cardiel MH: Direct cost of medical attention to Mexican patients with rheumatoid arthritis in a tertiary care
center. Clin Exp Rheumatol 15: 75-8. 1997.
Arnett FC, Edworthy SM, Bloch DA et al: The American Rheurnatism Association 1987 revised criteria for the classification of Rheumatoid Arthritis. Arthritis Rheum 31: 315-24. 1988.
Cardiel MH, Abello-Banfi M, Ruiz- Mercado R, Alarcon-Segovia D: How to measure health status in rheumatoid arthritis in non-English speaking patients:validation of a Spanish version of l-lealth Assessment Questionnaire Disabulity mdcx (Spanish-HAQ-Dl). Clin Exp Rheumatol 11: 117-21. 1993.
Clarke AE, Zowall H, Levinton C, et al: Direct and indirect medical cost incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheurnatol 24: 1051-60. 1997,
Hermida R y col: El Balance de la Economía Argentina en 2001: un enfoque regional. Bolsa de Comercio de Córdoba e Instituto de Investigaciones Económicas. Triunfar. Córdoba: 2001.
S. Lambert CM: Medical therapy for rheumatoid arthritis-value for money? Rheumatology 40: 961-4. 2001.
O'Brian Bernie: Statistical analysis of cost effectiveness data. J Rheumatol 26: 2078-80. 1999.
Prashker MJ, Meenan RF: The total cost of drug therapy for rheumatoid arthritis. A model based on cost of drug, monitoring and toxicity. Arthritis Rheum 3:318-25. 1995.
Revista KAIROS Argentina. Revista de ciencia y tecnología para la información del siglo XXI. Sociedad Impresora Americana SAIC. Año XXII - N° 268/Enero 2001.
Rothfuss J, Mau W, Zeidler H, Brenner MH: Socioeconomic evaluation of Rheumatoid Arthritis and Osteoarthritis: A literature review. Semin
Arthrltis Rheum. 26: 771-9. 1997.
Ruff B. OMERACT: Econornic evaluations and health policy. ,J Rheumatol 26: 2076-7. 1999.
Spindler A, Bellomio M, Berman A et al: Prevalence of rheumatoid arthritis in Tucumán, Argentina. J Rheumatol 29: 1166-9. 2002
Strusberg 1, Drenkard C, Roqué MH, Gamron S, Barberis O, Onetti CM. Análisis de pacientes ambulatorios que concurren por primera vez al Servicio de Reumatología de un hospital universitario: Rey Esp Reumat 27: 382- 7.2000.
Van Jaarsveld CHM, Jacobs JWG, Schrijvers AJP et al: Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. British J
Rheumatol 37: 837-47. 1998.
Van ,Jaarsveld CHM, Jacobs JWG, Schrijvers AJP, et al: Effects of rheumatoid arthritis on employment and social participation during the first year of disease in the Netherland. Br J Rheumatol 37: 848-53. 1998.
Yelin E, Callahan LF for the National Arthrtis Data Work Group: The economic cost and psychological impact of musculo-skeletal conditions. Arthritis Rheum 38: 1351-62. 1995.
Yelin E: The costs of rheumatoid arthritis: absolute, incrernental and marginal estimates. J Rheurnatol 23: 47- 51. 1996
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
